Literature DB >> 856436

Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.

E Cvitkovic, J Spaulding, V Bethune, J Martin, W F Whitmore.   

Abstract

Cis-Dichlorodiammineplatinum (CPDD) NSC 119875 was given at toxic doses (3 mg/kg) to three groups of dogs. The renal toxicity was avoided with massive prehydration and with mannitol induced diuresis. The bone marrow toxicity was unaltered by either manipulation. The data presented indicate that a better therapeutic index has been achieved by osmotic diuresis with mannitol. Blood levels and urine levels measurements show that the pharmacokinetics of the drug are unaltered, the urinary concentration of drug being low in the first few hours, but with similar urinary drug recovery in all three groups.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856436     DOI: 10.1002/1097-0142(197704)39:4<1357::aid-cncr2820390402>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Authors:  Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

Review 3.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

4.  Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats.

Authors:  N M Osman; M P Copley; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

Review 6.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

7.  Effect of osmotic diuresis on gentamicin-induced nephrotoxicity in rats.

Authors:  R A Newman; L B Weinstock; D W Gump; M P Hacker; J W Yates
Journal:  Arch Toxicol       Date:  1980-09       Impact factor: 5.153

8.  Cisplatin disposition in children and adolescents with cancer.

Authors:  W R Crom; W E Evans; C B Pratt; N Senzer; M Denison; A A Green; F A Hayes; G C Yee
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat.

Authors:  Dong Won Lee; Ihm Soo Kwak; Soo Bong Lee; Sang Heon Song; Eun Young Seong; Byeong Yun Yang; Min Young Lee; Mee Young Sol
Journal:  J Korean Med Sci       Date:  2009-01-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.